Cogentix Medical, Inc. (NASDAQ: CGNT) reported Q1 EPS of ($0.14), $0.04 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $11.2 million versus the consensus estimate of $11.34 million.

"We are pleased with our overall results for the quarter as our team executed on the revenue and cost synergies consistent with our merger integration strategy," said Rob Kill, President and CEO of Cogentix Medical. "Certainly, the highlight of the first quarter was the performance of our U.S. sales team, which delivered overall domestic revenue growth of 28% on a pro forma basis. Our innovative technologies address critical needs for our physician customers, and favorable market fundamentals should continue to drive demand for our products. For these reasons, today we are reaffirming our guidance for fiscal 2016."

For earnings history and earnings-related data on Cogentix Medical, Inc. (CGNT) click here.